Patient with Acute Hepatic Porphyria (AHP)
Ariel talks about her journey of finally receiving a diagnosis of acute hepatic porphyria (AHP), a rare disease characterized by potentially life-threatening pain attacks. She is now able to manage her disease. She also discusses her experience being treated with Alnylam Pharmaceutical‘s GIVLAARI™ (givosiran) a drug approved by the FDA in November 2019 for the treatment of AHP.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Treatment. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Treatment and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Treatment?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Ariel is a patient diagnosed with AHP while raising two young children. After experiencing her first excruciating pain attack in 2010, Ariel’s symptoms stumped doctors for months until she finally received an accurate diagnosis and is now managing her disease.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
